Financial toxicity experienced by patients with breast cancer-related lymphedema: a systematic review
Supportive Care in Cancer · 2023-06 · 31 (6)
DOI: 10.1007/s00520-023-07800-9 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Supportive Care in Cancer, online erschienen am 27.05.2023. Verfasst von Jingru Bian und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Nursing, Tianjin Medical University, 22 Qixiangtai Road, Heping District, Tianjin, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Breast Cancer Lymphedema, Lymphedema. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 36 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To perform a systematic review on financial toxicity of breast cancer-related lymphedema. METHODS: Seven databases were searched on September 11, 2022. Eligible studies were identified, analyzed, and reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Empirical studies were appraised by the Joanna Briggs Institute (JBI) tools. The Mixed Methods Appraisal Tool version 2018 was used to assess the mixed method studies. RESULTS: A total of 963 articles were identified, but only 7 articles reporting on 6 studies met the eligibility criteria. A 2-year treatment for lymphedema was approximately USD$14,877 to USD$23,167 in America. In Australia, the average out-of-pocket costs ranged from A$207 to A$1400 (USD$156.26 to USD$1056.83) per year. Outpatient visits, compressed clothing, and hospital admissions were the dominant costs. The financial toxicity was associated with the severity of lymphedema, and patients with heavy financial burden had to reduce other expenses or even forgo the treatment. CONCLUSION: Breast cancer-related lymphedema aggravated the economic burden of patients. The included studies showed great variation in the methods used and therefore differences in cost results. The national government should further improve the healthcare system and increase the insurance coverage of lymphedema treatment to alleviate this burden. More research is needed to focus on financial toxicity experience of breast cancer patients with lymphedema. IMPLICATIONS FOR CANCER SURVIVORS: The cost of the ongoing treatment of breast cancer-related lymphedema influences patients' economic situation and quality of life. Survivors need to be informed early about the potential financial burden associated with lymphedema treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Nursing, Tianjin Medical University, 22 Qixiangtai Road, Heping District, Tianjin, China.
- Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Immunology and Biotherapy, Key Laboratory of…
- Department of Nursing, Tianjin Medical University Cancer Institute & Hospital, Huanhuxi Road, Hexi District, Tianjin, China.
- Department of Medical & Surgical Nursing, School of Nursing, Peking University, No. 38 Xueyuan Road, Haidian District, Beijing, China.
- Tianjin University of Traditional Chinese Medicine, Beihuanan Road, Jinghai District, Tianjin, China.
- Department of Nursing, Tianjin Medical University Cancer Institute & Hospital, Huanhuxi Road, Hexi District, Tianjin, China. nursing1331@sina.com.
Zitieren
APA
Bian, J., Shen, A., Yang, W., Zhang, L., & Qiang, W. (2023). Financial toxicity experienced by patients with breast cancer-related lymphedema: a systematic review. Supportive Care in Cancer, 31(6). https://doi.org/10.1007/s00520-023-07800-9
Vancouver
Bian J, Shen A, Yang W, Zhang L, Qiang W. Financial toxicity experienced by patients with breast cancer-related lymphedema: a systematic review. Supportive Care in Cancer. 2023;31(6). doi:10.1007/s00520-023-07800-9
BibTeX
@article{Bian2023,
author = {Bian, Jingru and Shen, Aomei and Yang, Wanwan and Zhang, Liyuan and Qiang, Wanmin},
title = {Financial toxicity experienced by patients with breast cancer-related lymphedema: a systematic review},
journal = {Supportive Care in Cancer},
year = {2023},
volume = {31},
number = {6},
doi = {10.1007/s00520-023-07800-9}
}
EUVIMED